Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
This article was originally published in The Pink Sheet Daily
Executive Summary
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
You may also be interested in...
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
Chiron Expects Full Fluvirin Vaccine Production In 2006-2007
Fluvirin flu vaccine production capacity for 2005-2006 will be lower than the previous estimate of 18 mil.-25 mil. doses due to a shortened production season, CEO Pien says.